<DOC>
	<DOCNO>NCT00413361</DOCNO>
	<brief_summary>The main objective study PLUS determine potential benefit individualize HCQ dose schedule aim maintain whole-blood HCQ concentration 1000 ng/ml</brief_summary>
	<brief_title>The Reduction Systemic Lupus Erythematosus Flares : Study PLUS</brief_title>
	<detailed_description>Hydroxychloroquine ( HCQ ) treatment allow prevent Systemic Lupus Erythematosus ( SLE ) exacerbation . HCQ measure whole-blood HPLC ( High Performance Liquid Chromatography ) . Interindividual variability blood HCQ concentration important correlation HCQ level clinical efficacy HCQ demonstrate SLE monocentric study 143 unselected SLE patient . The main objective study PLUS determine potential benefit individualize HCQ dose schedule aim maintain whole-blood HCQ concentration 1000 ng/ml The secondary objective : - To define biological clinical hallmark present M1 ( month 1 ) predictor SLE exacerbation next 6 month , - To establish parameter HCQ pharmacokinetic model , study population , use `` Bay√©sienne '' approach . - To study influence allelic variant drug carrier gene interindividual variability blood HCQ concentration . - To study influence compliance blood HCQ concentration variability - To study relation blood HCQ concentration , SLE activity quality life - To study relation blood HCQ concentration , SLE activity lipid profile patient - To study relation ECG abnormalities blood HCQ concentration - To constitute bank serum , DNAbank , RNAbank permit subsequent study</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Age 18 Diagnosis Systemic Lupus Erythematosus ( SLE ) accord American College Rheumatology ( ACR ) Classification Criteria . Treatment HCQ least 6 month , without modification HCQ dosage 2 month Stable dosage HCQ one day another ( 200 g x 2/day 400 mg day 200 mg day ) No increase steroids dosage 3 previous week Steroids dosage low equal 0 . 5 mg/kg/day prednisone equivalent No modification possible immunosuppressor 2 previous month SELENASLEDAI &lt; = 12 Signature consent participation Known retinopathy , present pass Severe cataract obstruct ophthalmologic monitoring MONOPHTALM patient Past history intolerance HCQ ( particular gastrointestinal , retinal ) possible former use high dosage Use nivaquine 3 previous month Treatment biotherapy ( example Rituximab ) 12 previous month Calculated clearance creatinin low 60 ml/min Chronic alcoholism Liver failure Desire pregnancy next 7 month Known non compliance , risk random followup Absence social security cover People profit particular protection : Pregnant woman Age 18 Patient supervision TRUSTEESHIP People hospitalize without consent protect law People private freedom . Criteria inclusion visit randomization ( D0 ) : All patient respond next criterion randomize : Blood HCQ concentration range 100 750 ng/ml time visit preselection , No increase steroids dosage since last visit No modification possible immunosuppressor since last visit SELENASLEDAI &lt; = 12 Activity lupus remain stable ( increase 2 point SELENASLEDAI ) , Ophthalmologic examination 6 previous month contraindication use HCQ , Absences conductive disorder ECG Use effective contraception , Negative BetaHCG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Hydroxychloroquine</keyword>
</DOC>